Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.
Saved in:
| Title: | Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation. |
|---|---|
| Authors: | Schnappinger D; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, 10065, USA. dis2003@med.cornell.edu., Berthel SJ; Panorama Global, Seattle, WA, USA., Boshoff HIM; Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, 20892, USA., Krieger IV; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA., Sukheja P; Calibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA., Panda S; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA., Rath S; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA., Briggs K; Gates Medical Research Institute, Cambridge, MA, USA., Bian X; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA., Rasheed S; Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), PharmaScienceHub (PSH), Saarland University Campus, 66123, Saarbrücken, Germany., Cleghorn LAT; Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK., Ghorpade S; Holistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch, 7701, South Africa., Lamprecht DA; Holistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch, 7701, South Africa., Fotouhi N; TB Alliance: Global Alliance for Tuberculosis Drug Development, New York, NY, USA., Müller R; Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), PharmaScienceHub (PSH), Saarland University Campus, 66123, Saarbrücken, Germany., Nathan C; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, 10065, USA., Parish T; Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK., Rhee K; Division of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medicine, New York, NY, 10021, USA., Warner P; Gates Foundation, Seattle, WA, USA., McNamara CW; Calibr-Skaggs Institute for Innovative Medicines, A Division of Scripps Research, La Jolla, CA, USA., Rock JM; Laboratory of Host-Pathogen Biology, The Rockefeller University, New York, NY, 10065, USA., Sacchettini JC; Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA., Mizrahi V; Molecular Mycobacteriology Research Unit, Institute of Infectious Disease and Molecular Medicine & Department of Pathology, University of Cape Town, Cape Town, South Africa. Valerie.Mizrahi@uct.ac.za. |
| Source: | EMBO molecular medicine [EMBO Mol Med] 2026 May; Vol. 18 (5), pp. 1495-1507. Date of Electronic Publication: 2026 Apr 07. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1757-4684 |
|---|---|
| DOI: | 10.1038/s44321-026-00415-7 |
